Literature DB >> 28744666

Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants.

Kathrine Meyers1, Kristina Rodriguez1,2, Atrina L Brill3, Yumeng Wu1, Melissa La Mar1, Debora Dunbar4, Beryl Koblin5, David Margolis6, Magdalena E Sobieszczyk7, Hong Van Tieu5, Ian Frank8, Martin Markowitz1, Sarit A Golub9.   

Abstract

This study aimed to identify patients' physical and psychosocial experiences of an investigational long-acting injectable PrEP product to aid in the development of patient and provider education materials. Twenty-eight participants of a Phase 2 safety, tolerability, and acceptability study of long-acting integrase inhibitor cabotegravir (CAB-LA) were interviewed on their physical and psychosocial experiences of the injections. Five themes emerged through a framework analysis on these interview transcripts: (1) injection-related pain is highly variable across individuals; (2) pain is more impactful after the injections than during; (3) patient anxiety is critical, but does not determine the experience of injections and decreases over time; (4) intimacy and awkwardness of gluteal injections impacts patients' experiences; (5) patient education and care strategies can mitigate the above factors. These findings can inform further sociobehavioral research within Phase 3 efficacy trials of CAB-LA, as well as patient education and provider guidance for future injectable PrEP products.

Entities:  

Keywords:  HIV; Long-acting injectable; MSM; Patient education; PrEP; Providers

Mesh:

Substances:

Year:  2018        PMID: 28744666      PMCID: PMC5785575          DOI: 10.1007/s10461-017-1871-x

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  17 in total

1.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

2.  Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.

Authors:  Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden
Journal:  Lancet Infect Dis       Date:  2014-07-22       Impact factor: 25.071

3.  Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.

Authors:  David C Knox; Peter L Anderson; P Richard Harrigan; Darrell H S Tan
Journal:  N Engl J Med       Date:  2017-02-02       Impact factor: 91.245

4.  Non-occupational post-exposure prophylaxis for HIV: 10-year retrospective analysis in Seattle, Washington.

Authors:  Sarah J McDougal; Jeremiah Alexander; Shireesha Dhanireddy; Robert D Harrington; Joanne D Stekler
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

5.  Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

Authors:  Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant
Journal:  Sci Transl Med       Date:  2012-09-12       Impact factor: 17.956

6.  Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men.

Authors:  George J Greene; Greg Swann; Angela J Fought; Alex Carballo-Diéguez; Thomas J Hope; Patrick F Kiser; Brian Mustanski; Richard T D'Aquila
Journal:  AIDS Behav       Date:  2017-05

Review 7.  Human Papillomavirus Infection and Vaccination.

Authors:  Katie Valentino; Cathlin B Poronsky
Journal:  J Pediatr Nurs       Date:  2015-11-14       Impact factor: 2.145

8.  Use of modern contraception increases when more methods become available: analysis of evidence from 1982-2009.

Authors:  John Ross; John Stover
Journal:  Glob Health Sci Pract       Date:  2013-07-26

9.  Preexposure Prophylaxis Modality Preferences Among Men Who Have Sex With Men and Use Social Media in the United States.

Authors:  Eric William Hall; Walid Heneine; Travis Sanchez; Robert Craig Sineath; Patrick Sullivan
Journal:  J Med Internet Res       Date:  2016-05-19       Impact factor: 5.428

10.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

Authors:  Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill
Journal:  Lancet       Date:  2015-09-09       Impact factor: 79.321

View more
  16 in total

1.  Why I Quit Pre-Exposure Prophylaxis (PrEP)? A Mixed-Method Study Exploring Reasons for PrEP Discontinuation and Potential Re-initiation Among Gay and Bisexual Men.

Authors:  Thomas H F Whitfield; Steven A John; H Jonathon Rendina; Christian Grov; Jeffrey T Parsons
Journal:  AIDS Behav       Date:  2018-11

Review 2.  Mosaic effectiveness: measuring the impact of novel PrEP methods.

Authors:  David V Glidden; Megha L Mehrotra; David T Dunn; Elvin H Geng
Journal:  Lancet HIV       Date:  2019-09-27       Impact factor: 12.767

3.  "Talking About it Publicly Made Me Feel Both Curious and Embarrassed": Acceptability, Feasibility, and Appropriateness of a Stigma-Mitigation Training to Increase Health Worker Comfort Discussing Anal Sexuality in HIV Services.

Authors:  Bryan A Kutner; Yumeng Wu; Ivan C Balán; Kathrine Meyers
Journal:  AIDS Behav       Date:  2020-06

Review 4.  Practices of patient engagement in drug development: a systematic scoping review.

Authors:  Olga Zvonareva; Constanța Craveț; Dawn P Richards
Journal:  Res Involv Engagem       Date:  2022-06-29

5.  Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention.

Authors:  Pablo K Valente; Yumeng Wu; Yehuda Z Cohen; Marina Caskey; Kathrine Meyers
Journal:  Clin Trials       Date:  2020-08-24       Impact factor: 2.486

6.  Advancing Novel PrEP Products - Alternatives to Non-Inferiority.

Authors:  David V Glidden
Journal:  Stat Commun Infect Dis       Date:  2019-08-06

Review 7.  Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxis.

Authors:  David V Glidden
Journal:  Curr Opin HIV AIDS       Date:  2020-01       Impact factor: 4.061

Review 8.  Long-acting injectable cabotegravir for the prevention of HIV infection.

Authors:  Meredith E Clement; Ryan Kofron; Raphael J Landovitz
Journal:  Curr Opin HIV AIDS       Date:  2020-01       Impact factor: 4.061

Review 9.  Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals.

Authors:  Matthew R Beymer; Ian W Holloway; Craig Pulsipher; Raphael J Landovitz
Journal:  Curr HIV/AIDS Rep       Date:  2019-08       Impact factor: 5.495

10.  Transgender Women's Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP).

Authors:  Christine Tagliaferri Rael; Javier Lopez-Ríos; Stacey A McKenna; Doyel Das; Curtis Dolezal; Elena Abascal; Alex Carballo-Diéguez; Rebecca Schnall; Thomas J Hope; José Bauermeister; Walter Bockting
Journal:  AIDS Behav       Date:  2021-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.